Figure 5
LC3B protein levels are increased by bexarotene treatment in the peri-ischemic area of P301L-Tau TG mouse brains after stroke.
(A) Representative images showing LC3B immunoreactivity in the peri-ischemic area of WT and P301L-Tau TG mice at 12 days post-stroke. The boxes show select areas of the immunoreactivity at high magnification (B) LC3B immunoreactivity was quantified from three distinct brain areas represented by the rectangles. Analysis with 2-way ANOVA with Bonferroni post-tests within genotypes (C) The LC3B positive immunoreactive area was quantified from the peri-ischemic brain region. N = 7–8/group. (D) Representative image of LC3B Western blots run from samples of the peri-ischemic brain area of mice treated with bexarotene or vehicle 3 days after stroke. (E) Densitometry of LC3B-2 expression relative to β-actin. Analysis with unpaired t-test against vehicle, TG p = 0.031 N = 3–4/group. *p < 0.05. Scale bar 100 μM. a.u. = arbitrary unit.
